According to Protalix BioTherapeutics 's latest financial reports the company's current EPS (TTM) is $0.10. In 2022 the company made an earnings per share (EPS) of -$0.30 an increase over its 2021 EPS that were of -$0.62.
Year | EPS | Change |
---|---|---|
2023 (TTM) | $0.10000 | -133.33% |
2022 | -$0.30 | -51.61% |
2021 | -$0.62 | 342.86% |
2020 | -$0.14 | -88.71% |
2019 | -$1.24 | -34.74% |
2018 | -$1.90 | -70.92% |
2017 | -$6.53 | 2153.35% |
2016 | -$0.29 | -146.77% |
2015 | $0.62 | -287.88% |
2014 | -$0.33 | 10% |
2013 | -$0.30 | 130.77% |
2012 | -$0.13 | -56.67% |
2011 | -$0.30 | -46.43% |
2010 | -$0.56 | 36.59% |
2009 | -$0.41 | 32.26% |
2008 | -$0.31 | -93.4% |
2007 | -$4.70 | 1298.53% |
2006 | -$0.34 | -96.59% |
2005 | -$9.86 | 19.32% |
2004 | -$8.26 | 1552.65% |
2003 | -$0.50 | -0% |
2002 | -$0.50 | -50% |
2001 | -$1.00 |
Company | EPS | EPS differencediff. | Country |
---|---|---|---|
Pfizer PFE | $1.86 | 1,760.00% | ๐บ๐ธ USA |
Neurocrine Biosciences
NBIX | $1.96 | 1,860.00% | ๐บ๐ธ USA |
Amicus Therapeutics
FOLD | -$0.64 | -740.00% | ๐บ๐ธ USA |
Teva Pharmaceutical Industries TEVA | -$2.00 | -2,100.00% | ๐ฎ๐ฑ Israel |